Salarius Pharmaceuticals Announces Special Meeting for Reverse Stock Split

TL;DR

<b>Salarius Pharmaceuticals is holding a special meeting on May 9, 2024, to vote on a reverse stock split proposal.</b>

AI Summary

Salarius Pharmaceuticals, Inc. (DCOY) filed a Proxy Statement (DEF 14A) with the SEC on March 26, 2024. Salarius Pharmaceuticals will hold a Special Meeting of Stockholders on May 9, 2024, solely via live audio webcast. The primary item of business is to vote on a reverse stock split of common stock, with a ratio between 1:4 and 1:8. The Board of Directors will determine the exact ratio, timing, and execution of the reverse stock split. Stockholders must register by May 6, 2024, at 11:59 PM CT to attend the virtual meeting. The meeting agenda also includes a proposal to adjourn the meeting if necessary to solicit more proxies for the reverse stock split.

Why It Matters

For investors and stakeholders tracking Salarius Pharmaceuticals, Inc., this filing contains several important signals. A reverse stock split is often implemented to increase the stock price, potentially making it more attractive to institutional investors and avoiding delisting from exchanges. The company is seeking stockholder approval for this action, indicating a need for capital or strategic repositioning that may be hindered by a low stock price.

Risk Assessment

Risk Level: — Salarius Pharmaceuticals, Inc. shows moderate risk based on this filing. The company's stock performance and potential need for a reverse split suggest underlying financial or market challenges that could impact future value.

Analyst Insight

Stockholders should carefully consider the implications of the reverse stock split on their investment and the company's future strategy.

Key Numbers

• May 9, 2024 — Special Meeting Date (Date for the Special Meeting of Stockholders.)
• 1:4 to 1:8 — Reverse Stock Split Ratio Range (Proposed range for the reverse stock split.)
• May 6, 2024 — Registration Deadline (Deadline to register for the virtual meeting.)

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement.
• May 9, 2024 (date) — Date of the Special Meeting of Stockholders.
• 1:4 to 1:8 (dollar_amount) — Range of ratios for the proposed reverse stock split.
• May 6, 2024 (date) — Registration deadline for attending the virtual meeting.
• DEF 14A (filing) — Type of SEC filing.

FAQ

Risk Factors

• Reverse Stock Split Proposal [medium — financial]: The company seeks approval for a reverse stock split to potentially increase its stock price and meet exchange listing requirements.

Industry Context

Salarius Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.

Regulatory Implications

The filing is a Definitive Proxy Statement (DEF 14A) under the Securities Exchange Act of 1934, requiring specific disclosures for shareholder voting matters.

What Investors Should Do

1. Review the proxy statement for detailed information on the proposed reverse stock split and its potential impact.
2. Register to attend the Special Meeting by the May 6, 2024 deadline if you wish to participate.
3. Consider your voting strategy for the reverse stock split and adjournment proposals based on the company's disclosures and your investment goals.

Key Dates

• 2024-05-09: Special Meeting of Stockholders — To vote on a reverse stock split and adjournment proposal.
• 2024-05-06: Registration Deadline for Special Meeting — Last day for stockholders to register to attend the virtual meeting.

Glossary

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them. (Aims to increase the per-share market price, potentially improving stock appeal and exchange compliance.)

Proxy Statement

A document filed with the SEC that provides information to shareholders before a meeting where they will vote on corporate matters. (Details the proposals to be voted on, including the reverse stock split, and provides recommendations from the Board.)

Year-Over-Year Comparison

This filing is a DEF 14A, indicating a definitive proxy statement for a special meeting, distinct from regular periodic filings.

Key Financial Figures

• $85,000 — r a services fee not expected to exceed $85,000, plus the reimbursement of customary di

Filing Documents

• slrx-2023proxystatementspe.htm (DEF 14A) — 210KB
• screenshot2024-03x25152920a.gif (GRAPHIC) — 72KB
• screenshot2024-03x25153214a.jpg (GRAPHIC) — 200KB
• 0001615219-24-000030.txt (&nbsp;) — 586KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 20

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 20 OTHER MATTERS 22 APPENDIX A CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION, AS AMENDED, OF SALARIUS PHARMACEUTICALS, INC. 24 SALARIUS PHARMACEUTICALS, INC. PROXY STATEMENT INFORMATION CONCERNING VOTING AND SOLICITATION This Proxy Statement is being furnished to you in connection with the solicitation by the board of directors of Salarius Pharmaceuticals, Inc., a Delaware corporation, of your proxy to vote at our Special Meeting of Stockholders and any adjournments or postponements thereof (the "Special Meeting"). Our Special Meeting will be held at 1000 a.m., Central Time, on Thursday, May 9, 2024 via live webcast by first registering at httpwww.viewproxy.comslrx2024SM. You will receive a link by which to join the meeting upon registering to attend. As used in this Proxy Statement, references to "we," "us," "our," "Salarius" and the "Company" refer to Salarius Pharmaceuticals, Inc. and our consolidated subsidiaries. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this Proxy Statement and references to our website address in this Proxy Statement are inactive textual references only. QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Q Why am I receiving these materials A Our board of directors (the "Board of Directors" or the "Board") is soliciting your proxy to vote at our Special Meeting, including at any adjournments or postponements of the meeting. You are invited to attend the Special Meeting via the webcast to vote on the proposals described in the Proxy Statement. However, you do not need to attend the meeting to vote your shares. Instead, you may follow the instructions below to submit your proxy by telephone or through the Internet. We intend to mail the Notice of Internet Availability of Proxy Materials (the "Notice") on or about March 26, 2024 to all stockholders of record entit

View Full Filing

View this DEF 14A filing on SEC EDGAR